Mavrilimumab

Phase 2Monoclonal antibody

AstraZeneca

Mavrilimumab is one of 71 small molecule programs targeting Acute Respiratory Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Respiratory FailureActive, not recruiting

PneumoniaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Acute Respiratory FailurePhase 2

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Enbrel

IImmunex

Preclinical

64 3

Remicade

OOrganon and Co

Preclinical

43 4

Mavrilimumab

AstraZeneca

Phase 2

4 5

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 6

Celexa

AbbVie

Preclinical

1 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 9

Cataflam

Rituxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis4 trials

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01706926·420 enrolled

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01050998·516 enrolled

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT01712399·409 enrolled

Show 1 more trial

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01715896·215 enrolled

Acute Respiratory Failure3 trials

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed·VVirginia Commonwealth University·Phase 2·NCT04463004·2 enrolled

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed·KKristin Hudock·Phase 2·NCT04492514·1 enrolled

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Completed·TThe Cleveland Clinic·Phase 2·NCT04399980·40 enrolled

Pneumonia2 trials

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

Unknown status·OOspedale San Raffaele·Phase 2·NCT04397497·50 enrolled

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Completed·KKiniksa Pharmaceuticals International, plc·Phase 2/3·NCT04447469·814 enrolled

Double-blind1 trial

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02213315·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Mavrilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mavrilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mavrilimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Mavrilimumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Acute Respiratory Failure3 trials

Pneumonia2 trials

Double-blind1 trial

References

Drug Info

Quick Facts

Related News